RGNCY-0078 (8e LRRK2 inhibitor)
Compound 8e is an inhibitor of leucine-rich repeat kinase 2 (LRRK2) which has been suggested as a therapeutic target for Parkinson's disease. 8e demonstrates a good in vitro and in vivo pharmacokinetic profile with high exposure in both brain and and blood (Br/Bl ratio 1:3). This compound is orally bioavailable (F=91.6%) and highly tissue bound in mouse brain (99.7%). 8e is also highly selectivity across the kinome.
Systematic Name: 2-((4-fluorobenzyl)oxy)-N-(pyridin-3-yl)-5-(trifluoromethyl)benzamide
Molecular Weight: 390.34
Tags: Parkinson's, Parkinson, Parkinsons, RGNCY-0078, 8e, LRRK2